Pharmaceutical major Pfizer Inc. has entered into a funding agreement with Blackstone Inc. to secure up to $1.5 billion to support the development of an experimental obesity drug. Announced on Wednesday, the partnership provides Pfizer with additional financial backing as it works to enter the competitive weight-loss treatment market.
Under the terms of the agreement, funds managed by Blackstone Life Sciences will finance up to $1.5 billion in development costs through the year 2028. The funding is specifically designated for an obesity treatment that Pfizer is currently evaluating as a monthly weight-loss injection.
In return for its financial backing, Blackstone will be eligible to receive payments tied to specific sales milestones and US regulatory approval. Despite the funding arrangement, Pfizer will maintain full ownership and control of the medicine.
Pfizer is actively working to establish a presence in the growing weight-loss sector, where it faces established market leaders such as Eli Lilly & Co. and Novo Nordisk A/S. The company's expansion efforts follow its acquisition of Metsera Inc. for up to $10 billion last year. Additionally, Pfizer has outlined plans to advance more than 20 clinical trials within its obesity portfolio this year, a figure that includes 10 late-stage studies.
Cecile Guegan, Chief Financial Officer at Pfizer, noted in a company statement that the agreement will assist the pharmaceutical firm in pursuing its extensive obesity program while simultaneously allowing it to preserve resources for other therapeutic areas.
Blackstone has maintained an active role in funding pharmaceutical development in recent years. Among its previous transactions, the firm reached an agreement in 2024 to help finance clinical trials for Moderna Inc.’s influenza shot, which subsequently received US approval this summer.
"This funding arrangement demonstrates a strategic approach to capital allocation in the capital-intensive pharmaceutical sector. By partnering with private equity through Blackstone Life Sciences to fund high-cost clinical trials, Pfizer is able to mitigate financial exposure in a competitive therapeutic market while retaining full ownership of its intellectual property. For large enterprises and high-growth ventures alike, sharing development risk without diluting asset control is a practical model to finance ambitious pipelines and accelerate time to market." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
Recent StartupLanes Articles
Browse through our 30 latest publications on venture capital, startups, and angel investing.